Evidence map›Paper›PMID 39240481›Full record

ArticleFamilial cancer2024

Asymptomatic Bloom syndrome diagnosed by chance in a patient with breast cancer.

Evgeny Suspitsin, Darya Eliseyeva, Olga Chiryaeva, Evgeniya Belogubova, Svetlana Aleksakhina, Anna Sokolenko, Evgeny Imyanitov

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Familial cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Breast-Ovarian Hereditary Cancer Syndrome: BeyondCurrent oncology (Toronto, Ont.) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evgeny SuspitsinDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia.
Darya EliseyevaOncology Regional Hospital, Omsk, Russia.
Olga ChiryaevaDepartment of Medical Genetics, St. Petersburg State Pediatric Medical University, St. Petersburg, Russia.
Evgeniya BelogubovaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia.
Svetlana AleksakhinaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia.
Anna SokolenkoDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia. annasokolenko@mail.ru.ORCID 0000-0001-6304-1609
Evgeny ImyanitovDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia.

Funding

Russian Science Foundation 22-15-00266
6 · The paper itself

Abstract

Bloom syndrome (BS) is a rare genetic disorder caused by biallelic inactivation of the BLM gene, which usually manifests in childhood by significant growth retardation, immune deficiency, characteristic skin lesions, cancer predisposition and other distinguishable disease features. To our knowledge, all prior instances of BS have been identified via intentional analysis of patients with clinical suspicion for this disease or DNA testing of members of affected pedigrees. We describe an incidental finding of BS, which occurred upon routine germline DNA analysis of consecutive breast cancer patients. The person with the biallelic pathogenic BLM c.1642C>T (p.Gln548Ter) variant remained clinically healthy for 38 years until she developed breast cancer. Detailed examination of this woman, which was carried out after the genetic diagnosis, revealed mild features of BS. A sister chromatid exchange (SCE) test confirmed the presence of this syndrome. The tumor exhibited triple-negative receptor status, a high proliferation rate, a low tumor mutation burden (TMB), and a moderate level of chromosomal instability (homologous recombination deficiency (HRD) score = 29). The patient showed normal tolerability to radiotherapy and several regimens of cytotoxic therapy. Thus, some BS patients may remain undiagnosed due to the mild phenotype of their disease. BLM should be incorporated in gene panels utilized for germline DNA testing of cancer patients.

Indexed as

Bloom SyndromeBreast NeoplasmsRecQ HelicasesAdultAsymptomatic DiseasesFemaleGerm-Line MutationHumansIncidental FindingsMiddle AgedPedigreeBloom syndrome proteinRecQ HelicasesBLM geneBloom syndromeBreast cancerSister chromatid exchange

Identifiers

PMID39240481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.